Loading
A study that catalogued small RNAs made only by tumours and showed that their level in blood before and after chemotherapy tracked how breast cancer patients fared.
Across 32 tumour types the authors annotated orphan non-coding RNAs. In a retrospective study of 192 breast cancer patients from I-SPY 2, sampled before and after neoadjuvant chemotherapy, the abstract reports that oncRNAs are reliably detected in blood and that changes in cell-free oncRNA burden predict both short-term and long-term outcomes; the full text states that the change remained informative of survival when controlling for pathological complete response or residual cancer burden. The hazard ratios are given only in a figure and are not quoted here. The senior author co-founded Exai Bio.
The closest published result to an RNA residual disease test in breast cancer: a burden score that tracks outcome, without a stated detection limit.
Shares Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer, Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Naming which clone or phenotype is left after treatment, Minimal / molecular residual disease (MRD).
Shares Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer, Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Naming which clone or phenotype is left after treatment, Breast cancer (all types).
Shares Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer, Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Naming which clone or phenotype is left after treatment.
Shares Exai Bio, Liquid RNA biopsy (cell-free, vesicle and platelet RNA).
Shares Exai Bio, Liquid RNA biopsy (cell-free, vesicle and platelet RNA).
Shares Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer, Liquid RNA biopsy (cell-free, vesicle and platelet RNA).
Shares Naming which clone or phenotype is left after treatment, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Breast cancer (all types).
Shares Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer, Naming which clone or phenotype is left after treatment, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/